Volume 33, Issue 3 (June 2022)
Studies in Medical Sciences 2022, 33(3): 194-199 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Eini P, Hedayat Yaghoobi M, Tahai S M, Tahamoli Roudsari A, Seif-Rabiei M. COMPARISON OF SERUM LEVELS OF ANTI-CYCLIC CITRULLINATED PEPTIDE ANTIBODY (ANTI-CCP) AND RHEUMATOID FACTOR LEVEL IN BRUCELLOSIS PATIENTS WITH AND WITHOUT OSTEOARTICULAR SYMPTOMS. Studies in Medical Sciences 2022; 33 (3) :194-199
URL: http://umj.umsu.ac.ir/article-1-4260-en.html
URL: http://umj.umsu.ac.ir/article-1-4260-en.html
Peyman Eini * 
, Mojtaba Hedayat Yaghoobi , Seyede Mahsa Tahai , Ahmad Tahamoli Roudsari , Mohammad-Ali Seif-Rabiei
, Mojtaba Hedayat Yaghoobi , Seyede Mahsa Tahai , Ahmad Tahamoli Roudsari , Mohammad-Ali Seif-Rabiei
Department of Infectious Diseases, Hamadan University of Medical Sciences. Hamadan, Iran (Corresponding Author) , eini@umsha.ac.ir
Abstract: (1009 Views)
Background & Aim: Anti-CCP and rheumatoid factor are among the markers that can be positive in brucellosis patients and even have different levels in the patients with and without osteoarticular symptoms. This study was designed and implemented with the aim of comparison of anti-cyclic citrullinated peptide antibody and rheumatoid factor levels in brucellosis patients with and without osteoarticular symptoms.
Materials & methods: In this analytical-descriptive study, 106 brucellosis patients were examined. Anti-CCP antibody and RF levels were measured in patients with and without osteoarticular problems using ELISA method. The results were analyzed using SPSS version 16 software. P<0.05 was considered statistically significant.
Results: Among 106 patients, 68 (64.2%) were male and 38 (35.8%) were female. The mean age of the participants in the study was 33.5 years, with the age range of 20 to 55 years. 69 people (65.1%) had bone-joint symptoms, of which 72.5% had arthralgia and 19 (27.5%) had arthritis. About 60% of the patients with osteoarticular symptoms had spondylitis and the least involvement was observed in shoulder. Mean anti-CCP level in the patients with and without osteoarticular symptoms was 7.9 ± 4.9 and 5.4 ± 2.93 U/ml, respectively (P = 0.02). Although the mean rheumatoid factor and ESR levels in the patients with osteoarticular symptoms was higher than those without these problems, but the difference was not significant.
Conclusion: According to the results of the present study, the level of anti-CCP in brucellosis patients with involvement of the skeletal-motor system is higher than the patients without involvement of this system, which may be misdiagnosed with rheumatological diseases.
Materials & methods: In this analytical-descriptive study, 106 brucellosis patients were examined. Anti-CCP antibody and RF levels were measured in patients with and without osteoarticular problems using ELISA method. The results were analyzed using SPSS version 16 software. P<0.05 was considered statistically significant.
Results: Among 106 patients, 68 (64.2%) were male and 38 (35.8%) were female. The mean age of the participants in the study was 33.5 years, with the age range of 20 to 55 years. 69 people (65.1%) had bone-joint symptoms, of which 72.5% had arthralgia and 19 (27.5%) had arthritis. About 60% of the patients with osteoarticular symptoms had spondylitis and the least involvement was observed in shoulder. Mean anti-CCP level in the patients with and without osteoarticular symptoms was 7.9 ± 4.9 and 5.4 ± 2.93 U/ml, respectively (P = 0.02). Although the mean rheumatoid factor and ESR levels in the patients with osteoarticular symptoms was higher than those without these problems, but the difference was not significant.
Conclusion: According to the results of the present study, the level of anti-CCP in brucellosis patients with involvement of the skeletal-motor system is higher than the patients without involvement of this system, which may be misdiagnosed with rheumatological diseases.
References
1. Malani PN. Mandell, Douglas, and Bennett's principles and practice of infectious diseases. JAMA 2010;304(18):2583-9. [DOI:10.1001/jama.2010.1643]
2. Hasanjani Roushan MR، Moulana Z، Mohseni Afshar Z، Ebrahimpour S. Risk Factors for Relapse of Human Brucellosis. Glob J Health Sci 2015;8(7):77-82. [DOI:10.5539/gjhs.v8n7p77] [PMID] [PMCID]
3. Salata RA. Brucellosis. In: Arend WP، Armitage JO، Clemmons DR، editors. Cecil medicine. 23 ed. Philadelphia: WB Saunders; 2008. p. 2248-51.
4. Jow-Afshani MA, Zowghi E, Simani S. Major zoonoses in Iran. 1 ed. Tehran: Ministry of Health and Medical Education; 2005.
5. Mantur BG، Biradar MS، Bidri RC، Mulimani MS، Veerappa، Kariholu P، et al. Protean clinical manifestations and diagnostic challenges of human brucellosis in adults: 16 years' experience in an endemic area. J Med Microbiol 2006;55(Pt 7):897-903. [DOI:10.1099/jmm.0.46097-0] [PMID]
6. Mandell GL, Bennett JE, Dolin R. Principles and practice of infectious diseases. 6 ed. Philadelphia: Churchill Livingstone; 2005. p. 2669-72.
7. Gokhan A, Turkeyler IH, Babacan T, Pehlivan Y, Dag MS, Bosnak VK, et al. The antibodies cyclic citrullinated peptides (anti-CCP) positivity could be a promising marker in brucellosis patients presented with peripheric arthritis. Mod Rheumatol 2014;24(1):182-7. [DOI:10.3109/14397595.2013.854053] [PMID]
8. Aridoğan BC، Çetin ES، Yildirim M، Kaya S. Anti-cyclic citrullinated peptide antibodies in rheumatoid arthritis، brucellar arthritis and Behcet's. Afr J Microbiol Res 2011;23(5):2975-9. [DOI:10.5897/AJMR11.507]
9. Schellekens GA, Visser H, de Jong BA, van den Hoogen FH, Hazes JM, Breedveld FC, et al. The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide. Arthritis Rheum 2000;43(1):155-63.
https://doi.org/10.1002/1529-0131(200001)43:1<155::AID-ANR20>3.0.CO;2-3 [DOI:10.1002/1529-0131(200001)43:13.0.CO;2-3] [PMID]
10. Buzgan T, Karahocagil MK, Irmak H, Baran AI, Karsen H, Evirgen O, et al. Clinical manifestations and complications in 1,028 cases of brucellosis: a retrospective evaluation and review of the literatur. Int J Infect Dis 2010;14(6):469-78. [DOI:10.1016/j.ijid.2009.06.031] [PMID]
11. Ahmadinejad Z, Abdollahi A, Ziaee V, Domiraei Z, Najafizadeh SR, Jafari S, et al. Prevalence of positive autoimmune biomarkers in the brucellosis patients. Clin Rheumatol 2016;35(10):2573-8. [DOI:10.1007/s10067-016-3171-7] [PMID]
12. Kisacik B, Dag MS, Pehlivan Y, Ugurlu K, Mercan OK, Aydinli M, et al. Anti-cyclic citrullinated peptide (anti-CCP) antibodies with brucellosis. Rheumatol Int 2014;34(6):873-4. [DOI:10.1007/s00296-013-2777-1] [PMID]
13. Haj Abdolbaghi M, Rasooli Nejad M, Yaghoob Zadeh M. Epidemiological, clinical, diagnostic and therapeutic survey in 505 cases with Brucellosi. Tehran Univ Med J 2001;59(4):34-46. [Google Scholar]
14. Malik GM. A clinical study of brucellosis in adults in the Asir region of southern Saudi Arabia. Am J Trop Med Hyg 1997;56(4):375-7. [DOI:10.4269/ajtmh.1997.56.375] [PMID]
15. Tasbakan MI, Yamazhan T, Gokengin D, Arda B. Brucellosis: a retrospective evaluation. Trop Doct 2003;33(3):151-3. [DOI:10.1177/004947550303300310] [PMID]
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
